DE1809119A1 - Magnesium aspartate prepn for the treatment - of infarction conditions - Google Patents

Magnesium aspartate prepn for the treatment - of infarction conditions

Info

Publication number
DE1809119A1
DE1809119A1 DE19681809119 DE1809119A DE1809119A1 DE 1809119 A1 DE1809119 A1 DE 1809119A1 DE 19681809119 DE19681809119 DE 19681809119 DE 1809119 A DE1809119 A DE 1809119A DE 1809119 A1 DE1809119 A1 DE 1809119A1
Authority
DE
Germany
Prior art keywords
magnesium
treatment
prepn
magnesium aspartate
infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19681809119
Other languages
German (de)
Other versions
DE1809119C3 (en
DE1809119B2 (en
Inventor
Dr Franz Fischer
Dr Joachim Helbig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERLA PHARM
Original Assignee
VERLA PHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VERLA PHARM filed Critical VERLA PHARM
Priority to DE19681809119 priority Critical patent/DE1809119C3/en
Publication of DE1809119A1 publication Critical patent/DE1809119A1/en
Publication of DE1809119B2 publication Critical patent/DE1809119B2/en
Application granted granted Critical
Publication of DE1809119C3 publication Critical patent/DE1809119C3/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21S—NON-PORTABLE LIGHTING DEVICES; SYSTEMS THEREOF; VEHICLE LIGHTING DEVICES SPECIALLY ADAPTED FOR VEHICLE EXTERIORS
    • F21S8/00—Lighting devices intended for fixed installation
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21S—NON-PORTABLE LIGHTING DEVICES; SYSTEMS THEREOF; VEHICLE LIGHTING DEVICES SPECIALLY ADAPTED FOR VEHICLE EXTERIORS
    • F21S8/00—Lighting devices intended for fixed installation
    • F21S8/08—Lighting devices intended for fixed installation with a standard

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Magnesium aspartate hydrochloride, (prepared from Mg diaspartate and HCl), is used for the treatment of infarction, particularly in heart patients, and is superior to previously used Mg cpds.

Description

Infarktprophylaktikum Die vorliegende Erfindung betrifft ein Infarktprophylaktikum, das durch einen Gehalt an Magnesiummonoaspartahydrochlorid gekennzeichnet istc Magnesiummonoasparthydrochlorid der Formel ist eine farblose kristalline Substans (glasklare Platten und Säulen), die in Porm einer 1 %igen wässrigen Lösung ein pH von 4,5 - 4,8 ergibt und als 6 %ige 1-n-HCl-Lösung eine spezifische Drehung von +12,5 + 2 besitzt. Der Mischschmelzpunkt dieser Verbindung mit Dicyaniamid beträgt 188°C. Die Löslichkeit in Wasser beträgt 1:5 (kalt), während die Verbindung in Alkohol, Aceton und Chloroform schwer löslich ist.Infarct prophylactic agent The present invention relates to an infarct prophylactic agent which is characterized by a content of magnesium monoaspartahydrochloride c magnesium monoaspartic hydrochloride of the formula is a colorless crystalline substance (crystal clear plates and columns), which in the form of a 1% aqueous solution gives a pH of 4.5-4.8 and as a 6% 1-n-HCl solution a specific rotation of +12 , 5 + 2 owns. The mixed melting point of this compound with dicyaniamide is 188 ° C. The solubility in water is 1: 5 (cold), while the compound is sparingly soluble in alcohol, acetone and chloroform.

Das erfindungsgemässe Magnesiummonoaspartathydrochlorid lösst sich aus Magnesiumdiaspartat durch Zugabe von Chlorwasserstoff nach folgendem Reaktionsschama herstellen: Die Chlorwasserstoffsäure auß der Lösung des Magnesiumdiaspartate schnell zugesetzt werden, denn sobald Asparaginsäure ausfällt, bildet sich eine thixotrope Masse, welche sich nur schwer durchmischen laßt.The magnesium monoaspartate hydrochloride according to the invention can be prepared from magnesium diaspartate by adding hydrogen chloride according to the following reaction scheme: The hydrochloric acid from the solution of the magnesium diaspartate can be added quickly, because as soon as aspartic acid precipitates, a thixotropic mass is formed, which is difficult to mix.

Die Reaktion wird am zweckmäßigsten in einem wäßrigen Nediui unter Verwendung der stöchiometrischen Mangen der N tanten durchgeführt. Die ausgefallene Asparaginsäure wird nach beendeter Umsetzung abfiltriert. Naoh Einengen des Filtrats kristallisiert das erfindungsgemäße Magnesiummonoaspartathydrochlorid aus. Die Verbindung Itapun oh Ueblichen Methoden, beispielsweise durch Unkristallisation, gereinigt werden.The reaction is most conveniently carried out in an aqueous Nediui Using the stoichiometric amounts of the N aunts carried out. The unusual one Aspartic acid is filtered off after the reaction has ended. Then concentrate the filtrate The magnesium monoaspartate hydrochloride according to the invention crystallizes out. The connection Itapun was purified by the usual methods, for example by recrystallization will.

Das erfindungsgemäße Magnesiummonoaspartathydrochlorid zeichnet sich in Überraschender Weise durch eine sehr große Komplexstabilität aus. Diese Tatsache ist insofern besonders überraschend, als das entsprechende Magnesiumglutamathydrochlorid eine wesentlich geringere Komplexstabilität besitzt.The magnesium monoaspartate hydrochloride according to the invention is distinguished Surprisingly characterized by a very high complex stability. this fact is particularly surprising as the corresponding magnesium glutamate hydrochloride has a much lower complex stability.

Daher eignet sich die erfindungsgemäße Verbindung in hervorragender Weise zur Magnesiumtherapie, da diese Verbindung aufgrund der geschilderten Eigenschaften die Gewähr rur eine weitgehende Resorption und gute Organverteilung von Magnesium biotot und in dieser Hinsicht allen bisher bekanten anorganischen und organischen Verbindungen überlegen ist.Therefore, the compound of the present invention is particularly useful Way to magnesium therapy, as this compound is due to the properties described the guarantee of extensive absorption and good organ distribution of magnesium biotot and in this respect all inorganic and organic known so far Connections is superior.

Magnesiumverbindungen werden für die Harzinfarktprophylaxe seit einigen Jahren empfohlen. Der Grad des therapeutisch zu erwartcndon Effekts ist abhängig von der Magnesiummenge, die in den Körper eingebracht werden kann. Infolge der hohen Komplexkonstante wird das erfindungsgemäße verwendeteMagnesiummonoaspartathydroohlorid erheblich besser als alle bisher bekannten Magnesiumverbindungen resorbiert, so dass der Wirkungsgrad dieser Verbindung über demjenigen aller bisher bekannten Magnesiumverbindungen liegt.Magnesium compounds have been used for resin infarction prophylaxis for some Recommended for years. The degree of the therapeutically expected effect depends on the amount of magnesium that can be brought into the body. As a result of the high The magnesium monoaspartate hydrochloride used in the present invention becomes the complex constant considerable better absorbed than all previously known magnesium compounds, so that the efficiency this compound is above that of all previously known magnesium compounds.

Claims (1)

Patentanspruch Claim Infarktprophylaktikum, gekennzeichnet durch einem Gehalt an Magnesiummonoaspartathydrochlorid.Infarct prophylactic, characterized by a content of magnesium monoaspartate hydrochloride.
DE19681809119 1968-11-15 1968-11-15 Heart attack prophylactic Expired DE1809119C3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19681809119 DE1809119C3 (en) 1968-11-15 1968-11-15 Heart attack prophylactic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19681809119 DE1809119C3 (en) 1968-11-15 1968-11-15 Heart attack prophylactic

Publications (3)

Publication Number Publication Date
DE1809119A1 true DE1809119A1 (en) 1970-06-11
DE1809119B2 DE1809119B2 (en) 1973-05-17
DE1809119C3 DE1809119C3 (en) 1973-12-20

Family

ID=5713434

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19681809119 Expired DE1809119C3 (en) 1968-11-15 1968-11-15 Heart attack prophylactic

Country Status (1)

Country Link
DE (1) DE1809119C3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855289A (en) * 1984-06-04 1989-08-08 Wester Per O Combination of two active substances
CN105712895A (en) * 2014-12-04 2016-06-29 辽宁药联制药有限公司 Preparation method for magnesium aspartate hydrochloride trihydrate
CN106883135A (en) * 2015-12-16 2017-06-23 辽宁药联制药有限公司 A kind of method for preparing MAH bulk drug

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720288C2 (en) * 1977-05-05 1984-02-16 Verlapharm v. Ehrlich AG, Emmenbrücke Use of magnesium salts for the production of preparations for treating farm animals
DE3238118A1 (en) * 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing METHOD FOR PRODUCING COMPLEX COMPOUNDS FROM AMINODICARBONIC ACIDS, DUAL VALUE METALIONS AND HALOGENIDIONS
DE3814856A1 (en) * 1988-05-02 1989-11-16 Verla Pharm MEANS FOR PROPHYLAXIS OF THE HEART INFARM AND FOR PREVENTING THE REINFARK

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855289A (en) * 1984-06-04 1989-08-08 Wester Per O Combination of two active substances
CN105712895A (en) * 2014-12-04 2016-06-29 辽宁药联制药有限公司 Preparation method for magnesium aspartate hydrochloride trihydrate
CN106883135A (en) * 2015-12-16 2017-06-23 辽宁药联制药有限公司 A kind of method for preparing MAH bulk drug

Also Published As

Publication number Publication date
DE1809119C3 (en) 1973-12-20
DE1809119B2 (en) 1973-05-17

Similar Documents

Publication Publication Date Title
DE2745083A1 (en) HYDROXYDIPHOSPHONIC ACIDS
DE1809119A1 (en) Magnesium aspartate prepn for the treatment - of infarction conditions
DE1925230C3 (en) Process for the production of the antibiotic streptozotocin
DE3039997A1 (en) PHOSPHONOHYDROXYACETONITRILE, A METHOD FOR THE PRODUCTION THEREOF AND ITS USE AS AN INTERMEDIATE PRODUCT FOR THE PRODUCTION OF MEDICINAL PRODUCTS
DE944943C (en) Process for the preparation of sodium perborate trihydrate
DE2430550C2 (en) Ethanol-water solvates of sodium hexametaphosphate complexes of α-6-deoxy-5-hydroxy-tetracycline and a process for their preparation
DE1809120A1 (en) Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments
DE1145588B (en) Process for the production of pure sodium hypophosphite
DE1809121A1 (en) Magnesium monoaspartate hydrobromide useful - as a sectative or tranquilliser
DE944953C (en) Process for the preparation of a therapeutic agent consisting of the calcium salt of Ca-ethylene diamine tetraacetic acid
DE595928C (en) Process for the production of thiourea
DE525651C (en) Process for the production of stable complex compounds of pentavalent antimony which are soluble in water
DE713079C (en) Process for the preparation of clusters of 4-aminobenzenesulfonamides
DE2745084A1 (en) 5-Keto-piperazine-2,2-di:phosphonic acid derivs. - useful as chelating agents e.g. in water treatment, for providing trace elements and treating metabolic disorders
AT216141B (en) Process for the preparation of the new dihydrate of the calcium salt of phenoxymethylpenicillin
DE1809118A1 (en) Mono magnesium aspartate hydrofluoride
DE2501959C2 (en) Method of making K? X? H? 3?? -?? X? PO? 4?
DE398406C (en) Process for the production of aluminum formate solutions
DE1924174C3 (en) Magnesium Orotate Glycinate
DE955592C (en) Process for the preparation of crystallizable mixed salts of dihydrostreptomycin which are difficult to dissolve in water
DE870276C (en) Process for the preparation of a double salt of p-amino-salicylic acid
DE1270540B (en) Process for the preparation of water-soluble complex compounds of aliphatic oxycarboxylic acids
DE2318043C3 (en) Bis-square brackets on 4,7-dihydroxycumarinyl- (3) square brackets acetic acid and its pharmacologically acceptable salts as well as processes for their production and pharmaceuticals containing these compounds
DE947333C (en) Process for the production of crystallized islet hormone preparations
DE637188C (en) Process for the production of theophylline or theobromine compounds of mercury compounds of the urethane series

Legal Events

Date Code Title Description
SH Request for examination between 03.10.1968 and 22.04.1971
C3 Grant after two publication steps (3rd publication)